Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617

por Umbricht, Christoph A., Gracheva, Nadezda, Johnston, Karl, Schibli, Roger, van der Meulen, Nicholas P., Müller, Cristina, Bernhardt, Peter, Koster, Ulli
Publicado 2019

Alpha-PET for Prostate Cancer: Preclinical investigation using (149)Tb-PSMA-617

por Umbricht, Christoph A., Köster, Ulli, Bernhardt, Peter, Gracheva, Nadezda, Johnston, Karl, Schibli, Roger, van der Meulen, Nicholas P., Müller, Cristina
Publicado 2019

Production and characterization of no-carrier-added (161)Tb as an alternative to the clinically-applied (177)Lu for radionuclide therapy

por Gracheva, Nadezda, Müller, Cristina, Talip, Zeynep, Heinitz, Stephan, Köster, Ulli, Zeevaart, Jan Rijn, Vögele, Alexander, Schibli, Roger, van der Meulen, Nicholas P.
Publicado 2019

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer

por Müller, Cristina, Umbricht, Christoph A., Gracheva, Nadezda, Tschan, Viviane J., Pellegrini, Giovanni, Bernhardt, Peter, Zeevaart, Jan Rijn, Köster, Ulli, Schibli, Roger, van der Meulen, Nicholas P.
Publicado 2019